Description
Latin name
NEOTON
Release form
Lyophilized powder for solution for infusion.
Packaging
4 vials.
Pharmacological action of
Phosphocreatine plays an important role in the energy mechanism of muscle contraction. It is an energy reserve in the cells of the myocardium and skeletal muscles and is used for the re-synthesis of adenosine triphosphoric acid (ATP), during the hydrolysis of which energy is released to ensure the actomyosin reduction process.
Insufficient intake of energy in cardiomyocytes, associated with a slowdown in oxidative processes, is a key mechanism for the development and progression of myocardial damage. The lack of phosphocreatine leads to a decrease in the strength of myocardial contraction and its ability to functionally recover. With myocardial damage, there is a close correlation between the amount of energy-rich phosphorylated compounds in cells, cell viability, and their ability to restore contractility.
Preclinical and clinical studies have demonstrated the cardioprotective effect of phosphocreatine, which is manifested in a dose-dependent positive effect on the toxic effects of isoprenaline, thyroxine, emethine, p-nitrophenol on the myocardium in a positive inotropic effect with a deficiency of glucose, calcium ions or with an overdose of potassium ions actions due to anoxia. Moreover, the addition of phosphocreatine to cardioplegic solutions at a concentration of 10 mmol / l improves the cardioprotective effect:
• reduces the risk of myocardial ischemia with cardiopulmonary bypass surgery
• reduces the risk of reperfusion arrhythmia with infusion prior to the development of regional regional ischemia before coronary artery
for 15 min • reduces the degradation of ATP and phosphocreatine in myocardial cells, preserves the structure of mitochondria and sarco lemma, improves the process of functional recovery of the myocardium after cardiac arrest caused by the introduction of a large dose of potassium, and reduces the frequency of reperfusion arrhythmias.
Phosphocreatine has a cardioprotective effect in the experiment with myocardial infarction and arrhythmia, caused by occlusion of the coronary artery: preserves the cell pool of adenine nucleotides by inhibiting the enzymes that cause their catabolism, inhibits the degradation of phospholipids, possibly improves microcirculation in the ischemic zone, which, due to the suppression of mediated adenosine diphosphoric acid platelet aggregation, stabilizes the heme platelet indices, stabilizes the heme platelet indices It has an antiarrhythmic effect, reduces the frequency and duration of ventricular fibrillation and ogre Anichitis myocardial infarction zone.
Indications
Neoton is used as a combination therapy for the following diseases:
• acute myocardial infarction
• chronic heart failure
• intraoperative myocardial ischemia
• intraoperative ischemia of the lower extremities, as well as in the treatment of acute sports syndromes improve the adaptation of athletes to extreme physical activity
Contraindications
hypersensitivity to the drug
chronic renal failure (when using the drug in doses of 5 – 10 g / day)
age 18 years (efficacy and safety have not been established).
Use during pregnancy and lactation
Data on the safety and effectiveness of the drug Neoton during pregnancy and lactation (breastfeeding) are not available.
Dosage and administration of
ONLY INTRAVENOUS (drip or as a quick infusion)
Acute myocardial infarction
1 day: 2-4 g of the drug, diluted in 50 ml of water for injection, in the form of an intravenous rapid infusion followed by a / in an infusion of 8-16 g in 200 ml of a 5% solution of dextrose (glucose) for 2 hours
2 days: 2-4 g in 50 ml of water for intravenous drip injection (infusion duration of at least 30 minutes) 2 times / day
3 days: 2 g in 50 ml of water for injection in / drip (infusion duration of at least 30 minutes) 2 times / day.
If necessary, a course of infusion of 2 g of the drug 2 times / day. can be carried out for 6 days.
Chronic heart failure
Depending on the patient’s condition, treatment with “shock” doses of 5-10 g of the drug in 200 ml of 5% dextrose / glucose iv solution can be started at a drop rate of 4-5 g / h for 3-5 days, and then switch to iv drip (duration of infusion for at least 30 minutes) 1–2 g of the drug, diluted in 50 ml of water for injection, 2 times / day. within 2-6 weeks or immediately start in / in the drip of maintenance doses of the drug Neoton (1-2 g in 50 ml of water for injection 2 times / day. for 2-6 weeks).
Intraoperative myocardial ischemia
An intravenous drip infusion course of at least 30 minutes for 2 g of the drug in 50 ml of water for injection 2 times / day is recommended. within 3-5 days, prior to surgery, and within 1-2 days after it. During surgery, Neoton is added to a standard cardioplegic solution at a concentration of 10 mmol / l or 2.5 g / l immediately before administration.
Intraoperative lower limb ischemia
2-4 g of Neoton in 50 ml of water for injection in the form of iv rapid infusion before surgery followed by iv drip of 8-10 g of the drug in 200 ml of 5% dextrose (glucose) solution at a speed of 4-5 g / h during surgery and during reperfusion.
In sports medicine, to prevent the development of acute and chronic physical stress syndrome and improve athletes’ adaptation to extreme physical exertion, Neoton should be used at a dose of 1 g / day in 50 ml of water for intravenous drip injection (infusion duration of at least 30 minutes) within 3-4 weeks.
Side effects
Hypersensitivity to the drug, lowering blood pressure (with rapid intravenous administration).
Overdose
There have been no reports of an overdose of Neoton at this time.
Storage conditions
The drug should be stored at room temperature.
The Expiration of
is 3 years.
Active ingredient
Phosphocreatine
pharmacy terms for prescription
dosage form
dosage form
infusion solution
Alfa Wasserman, Italy
